Ritlecitinib

Ritlecitinib
Clinical data
Trade names	Litfulo
Other names	PF-06651600
License data	US DailyMed: Ritlecitinib;
Routes of; administration	By mouth
ATC code	L04AF08 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one;
CAS Number	1792180-81-4; 2192215-81-7;
PubChem CID	118115473;
IUPHAR/BPS	9559;
DrugBank	DB14924;
ChemSpider	59718512;
UNII	2OYE00PC25; EAG4T1459K;
KEGG	D11970;
ChEMBL	ChEMBL4085457;
Chemical and physical data
Formula	C15H19N5O
Molar mass	285.351 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=C3C=CNC3=NC=N2;
	InChI InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1; Key:CBRJPFGIXUFMTM-WDEREUQCSA-N; Key:YOZLVAFWYLSRRN-VZXYPILPSA-N;

Ritlecitinib, sold under the brand name Litfulo, is a medication used for the treatment of severe alopecia areata (hair loss).^[1] Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase.^[1]^[4]^[5]

Ritlecitinib was approved for medical use in the United States in June 2023,^[1]^[6] and the European Union in September 2023.^[2]

Medical uses

Ritlecitinib is indicated for the treatment of severe alopecia areata for individuals aged 12 and over.^[1]^[2]

The annual list price of a prescription is $49,000. ^[7]

^ ^a ^b ^c ^d ^e "Litfulo- ritlecitinib capsule". DailyMed. U.S. National Library of Medicine. 23 June 2023. Archived from the original on 29 August 2023. Retrieved 28 August 2023.
^ ^a ^b ^c "Litfulo EPAR". European Medicines Agency. 18 September 2023. Archived from the original on 19 September 2023. Retrieved 20 September 2023.
^ "Litfulo Product information". Union Register of medicinal products. 18 September 2023. Archived from the original on 1 October 2023. Retrieved 1 October 2023.
^ "Ritlecitinib". Inxight Drugs. Archived from the original on 25 June 2023. Retrieved 24 June 2023.
^ Ramírez-Marín HA, Tosti A (February 2022). "Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata". Drug Design, Development and Therapy. 16: 363–374. doi:10.2147/DDDT.S334727. PMC 8860347. PMID 35210753.
^ "FDA Approves Pfizer's Litfulo (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata" (Press release). Pfizer. 23 June 2023. Archived from the original on 25 June 2023. Retrieved 24 June 2023 – via Business Wire.
^ Kansteiner F (26 June 2023). "Pfizer's Litfulo enters the scene in alopecia with adolescent nod to rival Lilly's Olumiant". Fierce Pharma. Archived from the original on 8 July 2023. Retrieved 18 September 2023.

Clinical trial number NCT03732807 for "PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.